Syneos Health Expands China Operations with Bestudy CRO Acquisition

Key Takeaways

• Syneos acquires Bestudy, expanding Chinese CRO network.
• Bestudy retains brand, operating independently under Syneos.
• China trial sites grew 51% (2023‑2025), outpacing US.
• NMPA halves review timelines to 30 days.
• Syneos' 2023 $7.1B buyout gives growth flexibility.

Summary

Syneos Health completed the acquisition of Shanghai‑based Bestudy Medical Technology on March 20, 2026, adding a fast‑growing Chinese CRO to its global network. Financial terms were not disclosed, and Bestudy will continue operating independently under its own brand. The deal builds on Syneos’ 2023 $7.1 billion take‑private transaction, giving the firm flexibility to pursue long‑term growth in China’s expanding clinical‑trial ecosystem. It also extends Syneos’ earlier partnership with Wuhan Union Hospital, deepening its reach with multinational pharma and emerging Chinese biotech firms.

Pulse Analysis

Syneos Health’s purchase of Bestudy Medical Technology marks a decisive step toward consolidating its presence in China, the world’s fastest‑growing biopharma market. By integrating Bestudy’s local expertise while preserving its brand and operating model, Syneos can offer seamless end‑to‑end services to both multinational sponsors and home‑grown innovators. This strategic fit complements the firm’s broader expansion agenda, which includes a 2023 private‑equity buyout that freed it from quarterly market pressures and enabled longer‑term investments in high‑growth regions.

China’s clinical‑trial landscape is undergoing a transformation that rivals the United States. The number of trial sites surged 51% between 2023 and 2025, and the National Medical Products Administration recently cut review timelines for novel drug trials from 60 to 30 working days. These regulatory accelerations, combined with a sophisticated, cost‑efficient ecosystem, are attracting global sponsors seeking speed and scale. As a result, multinational pharma is increasingly allocating budgets to Chinese sites, reshaping global trial geography and intensifying competition among CROs.

For Syneos, the acquisition dovetails with a broader industry trend of selective, high‑value deals amid economic uncertainty. The firm’s 2023 $7.1 billion take‑private transaction provided the capital flexibility to pursue strategic growth without the constraints of public‑market reporting. Coupled with recent survey data showing that biopharma capital remains active but more concentrated, Syneos is well‑positioned to leverage its expanded Chinese footprint, capture higher‑margin late‑stage projects, and drive sustainable revenue growth in the next decade.